相关实验视频
Updated: Jan 6, 2026
01:19
Mitral Valve Prolapse III: Nursing Management
Published on: June 19, 2025
252
氧化应激介于瘤缩因子-α诱导的线粒体DNA损伤和心脏肌细胞的功能障碍
Nobuhiro Suematsu1, Hiroyuki Tsutsui, Jing Wen
1Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Circulation
|March 19, 2003
概括
瘤坏死因子-α (TNF-α) 触发了心脏细胞中的反应性氧物种 (ROS) 生产和线粒体DNA (mtDNA) 损伤,导致心脏衰竭. ангиотензин II (Ang II) 增加ROS,但不会损害mtDNA.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 瘤缩因子-α (TNF-α) 和血管素II (Ang II) 与心力衰竭的进展有关,可能是通过活性氧物种 (ROS).
- 激动剂诱导的ROS产生的精确机制及其对心脏肌细胞,特别是线粒体DNA (mtDNA) 的影响尚不清楚.
- 之前的研究表明,ROS升高,mtDNA损伤和心脏衰竭的功能障碍之间存在相关性.
研究的目的:
- 调查心脏肌细胞在体外直接接触TNF-alpha和Ang II是否会通过ROS产生mtDNA损伤.
- 阐明涉及TNF-α介导ROS产生和随后mtDNA损伤的信号通路.
主要方法:
- 培养的新生小鼠心室肌细胞暴露于TNF-alpha和Ang II.
- 反应性氧物种 (ROS) 的产生被评估使用2',7'-二二氨酸二酸盐光.
- 线粒体DNA (mtDNA) 副本数量由南方斑点分析量化.
- 使用D609和C2-ceramide. 的方法检查了基米林-胺路径的作用.
主要成果:
- TNF-α显著增加了ROS的产生,并减少了肌细胞中的mtDNA拷贝数.
- 由TNF-alpha诱导的mtDNA拷贝数的减少与III复合体活性降低有关,并被α-托科菲罗尔阻止.
- 过氧化 (H2O2) 暴露模仿了mtDNA复制数的减少.
- 格II增加了ROS,但没有影响mtDNA拷贝数.
- 脊髓酶抑制剂D609和C2-胺阻断了TNF-α介导的ROS产生和mtDNA损伤,涉及脊髓胺-胺通路.
结论:
- TNF-α通过基胺-胺通路诱导心肌细胞ROS产生和mtDNA损伤.
- 这种TNF-alpha,ROS和mtDNA损伤之间的联系是肌肉心脏重塑和心力衰竭的潜在贡献者.
- 尽管具有类似的ROS诱导作用,但 ангиотензин II 在mtDNA损伤中的作用似乎与TNF-alpha不同.
相关概念视频
Mitral Valve Prolapse III: Nursing Management
252
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
252
Cancer Vaccines
917
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
917
Development of Immunocompetence
759
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
759
Vaccinations
51.1K
Overview
51.1K
Healthcare Associated Infections II: Preventive Measures
3.5K
Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
3.5K
Teratogenicity
3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K